The recommendation doesn't mean Wegovy is funded yet in Ireland. The HSE still has to decide whether it will pay for the obesity drug.
Recap by typeshit. Post by Facebook on Facebook.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
FOX29 WFLX reports on new research showing a shift from weight loss surgery to GLP-1 medications, with insurance coverage still standing in the way for some patients.
Boots added GLP-1 support zones in 220 stores, and Vesper Tool links GLP-1 protein needs to whey prices up roughly five-fold since 2023.
Loading…